TY - JOUR
T1 - ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
AU - Ahn, Young Ho
AU - Gibbons, Don L.
AU - Chakravarti, Deepavali
AU - Creighton, Chad J.
AU - Rizvi, Zain H.
AU - Adams, Henry P.
AU - Pertsemlidis, Alexander
AU - Gregory, Philip A.
AU - Wright, Josephine A.
AU - Goodall, Gregory J.
AU - Flores, Elsa R.
AU - Kurie, Jonathan M.
PY - 2012/9/4
Y1 - 2012/9/4
N2 - Metastatic cancer is extremely difficult to treat, and the presence of metastases greatly reduces a cancer patient's likelihood of long-term survival. The ZEB1 transcriptional repressor promotes metastasis through downregulation of microRNAs (miRs) that are strong inducers of epithelial differentiation and inhibitors of stem cell factors. Given that each miR can target multiple genes with diverse functions, we posited that the prometastatic network controlled by ZEB1 extends beyond these processes. We tested this hypothesis using a mouse model of human lung adenocarcinoma metastasis driven by ZEB1, human lung carcinoma cells, and human breast carcinoma cells. Transcriptional profiling studies revealed that ZEB1 controls the expression of numerous oncogenic and tumor-suppressive miRs, including miR-34a. Ectopic expression of miR-34a decreased tumor cell invasion and metastasis, inhibited the formation of promigratory cytoskeletal structures, suppressed activation of the RHO GTPase family, and regulated a gene expression signature enriched in cytoskeletal functions and predictive of outcome in human lung adenocarcinomas. We identified several miR-34a target genes, including Arhgap1, which encodes a RHO GTPase activating protein that was required for tumor cell invasion. These findings demonstrate that ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression and provide a compelling rationale to develop miR-34a as a therapeutic agent in lung cancer patients.
AB - Metastatic cancer is extremely difficult to treat, and the presence of metastases greatly reduces a cancer patient's likelihood of long-term survival. The ZEB1 transcriptional repressor promotes metastasis through downregulation of microRNAs (miRs) that are strong inducers of epithelial differentiation and inhibitors of stem cell factors. Given that each miR can target multiple genes with diverse functions, we posited that the prometastatic network controlled by ZEB1 extends beyond these processes. We tested this hypothesis using a mouse model of human lung adenocarcinoma metastasis driven by ZEB1, human lung carcinoma cells, and human breast carcinoma cells. Transcriptional profiling studies revealed that ZEB1 controls the expression of numerous oncogenic and tumor-suppressive miRs, including miR-34a. Ectopic expression of miR-34a decreased tumor cell invasion and metastasis, inhibited the formation of promigratory cytoskeletal structures, suppressed activation of the RHO GTPase family, and regulated a gene expression signature enriched in cytoskeletal functions and predictive of outcome in human lung adenocarcinomas. We identified several miR-34a target genes, including Arhgap1, which encodes a RHO GTPase activating protein that was required for tumor cell invasion. These findings demonstrate that ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression and provide a compelling rationale to develop miR-34a as a therapeutic agent in lung cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84865973348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865973348&partnerID=8YFLogxK
U2 - 10.1172/JCI63608
DO - 10.1172/JCI63608
M3 - Article
C2 - 22850877
AN - SCOPUS:84865973348
SN - 0021-9738
VL - 122
SP - 3170
EP - 3183
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 9
ER -